Our further study showed that the prominent expression of SMYD5 could promote the proliferation and inflammation in FLS, while knockdown of SMYD5 improved the aforementioned IL-1β-induced-FLS phenotype, suggesting that SMYD5 may be a potential therapeutic target for RA treatment. This evidence concerns the gene SMYD5 and rheumatoid arthritis.